Literature DB >> 14581804

CagA antibodies as a marker of virulence in chilean patients with Helicobacter pylori infection.

Paul R Harris1, Alex Godoy, Silvana Arenillas, Francisca Riera, Daniela García, Helly Einisman, Alfredo Peña, Antonio Rollán, Ignacio Duarte, Ernesto Guiraldes, Guillermo Perez-Perez.   

Abstract

BACKGROUND: The bacterial and host factors that influence the clinical outcomes of the Helicobacter pylori infection have not been fully identified. Cytotoxin-associated gene product (CagA), one of the virulence factors, has been associated with a more aggressive form of infection. The authors studied the relationship between CagA status and clinical outcome in Chilean children and adults with H. pylori infection.
METHODS: One hundred eighty consecutive patients undergoing upper gastrointestinal endoscopic analysis were enrolled after informed consent was obtained. Rapid urease test and histologic analysis were used to detect H. pylori infection. IgA and IgG antibodies to H. pylori whole cell antigen preparation and IgG antibodies to CagA were measured by enzyme-linked immunosorbent assay (ELISA).
RESULTS: H. pylori infection was detected in 42% of the patients by biopsy or urease test and in 38% and 20% of patients by IgG and IgA antibodies, respectively. The prevalence of H. pylori either by the invasive or the serologic tests was directly related to patient age. Among patients with H. pylori, there was no significant association between age and prevalence of CagA. Nearly 70% of the patients with H. pylori and peptic ulcer disease had CagA-positive strains. In contrast, only 49% of the patients with chronic gastritis alone had CagA-positive strains (P < 0.05).
CONCLUSIONS: In Chile, patients infected with H. pylori have a proportion of CagA-positive strains similar to that reported in developed countries. CagA prevalence was not significantly different in adults and children infected with H. pylori, suggesting that variations in clinical outcome may be related to host immune or environmental factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581804     DOI: 10.1097/00005176-200311000-00018

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Relevance of adjusted cut-off values in commercial serological immunoassays for Helicobacter pylori infection in children.

Authors:  Paul Harris; Guillermo Perez-Perez; Alejandro Zylberberg; Antonio Rollán; Carolina Serrano; Francisca Riera; Helly Einisman; Daniela García; Paola Viviani
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

2.  Relationship between Helicobacter pylori virulence factors and regulatory cytokines as predictors of clinical outcome.

Authors:  Carolina Serrano; Maria Ines Diaz; Alejandra Valdivia; Alex Godoy; Alfredo Peña; Antonio Rollan; Arturo Kirberg; Eduardo Hebel; Jaqueline Fierro; Gabriela Klapp; Alejandro Venegas; Paul R Harris
Journal:  Microbes Infect       Date:  2007-01-12       Impact factor: 2.700

3.  CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation.

Authors:  Semra Sökücü; Ayşe Tülin Ozden; Ozlem Durmaz Süoğlu; Berna Elkabes; Fikri Demir; Uğur Cevikbaş; Selim Gökçe; Günay Saner
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

Review 4.  Role of childhood infection in the sequelae of H. pylori disease.

Authors:  Paul R Harris; Lesley E Smythies; Phillip D Smith; Guillermo I Perez-Perez
Journal:  Gut Microbes       Date:  2013-11-06

5.  Helicobacter pylori cagA+ Is Associated with Milder Duodenal Histological Changes in Chilean Celiac Patients.

Authors:  Yalda Lucero; Amaya Oyarzún; Miguel O'Ryan; Rodrigo Quera; Nelly Espinosa; Romina Valenzuela; Daniela Simian; Elisa Alcalde; Claudio Arce; Mauricio J Farfán; Alejandra F Vergara; Iván Gajardo; Jocelyn Mendez; Jorge Carrasco; Germán Errázuriz; Mónica Gonzalez; Juan C Ossa; Eduardo Maiza; Francisco Perez-Bravo; Magdalena Castro; Magdalena Araya
Journal:  Front Cell Infect Microbiol       Date:  2017-08-23       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.